Drug intelligence / Profile preview

antithymocyte globulin

Development stage
Phase 4
Lead developer
Sanofi
Modality
Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

Antithymocyte globulin is a polyclonal antibody preparation derived from the serum of rabbits or horses immunized with human thymocytes. It is an immunosuppressive biologic used primarily for the prophylaxis and treatment of acute rejection in organ transplantation, especially kidney transplants, and for the treatment of moderate to severe aplastic anemia. The drug works by binding to multiple T-cell surface antigens, leading to T-cell depletion through complement-mediated cytotoxicity and apoptosis. This results in profound suppression of cell-mediated immunity[1][2][3][5][8]. Rabbit-derived preparations are marketed as Thymoglobulin, while horse-derived versions are known as Atgam.

Brand names
AtgamThymoglobulin
Other names
antithymocyte immune globulinanti-thymocyte globulinantithymocyte immunoglobulin
02

Targets

IL2RA (Interleukin-2 receptor alpha subunit)CD2 (T-cell Surface Antigen CD2)ITGB2 (Complement receptor 4)ITGAL (Integrin alpha L (CD11a))HLA-DR (Human leukocyte antigen DR)MHC I (MHC class I})CD8A (CD8 alpha/beta Coreceptor)CD44 (CD44 antigen)CD4 (T lymphocyte surface antigen)CD3 (T-cell surface glycoprotein CD3)PTPRC (Receptor-type tyrosine-protein phosphatase C)

Beyond the preview

Go deeper on antithymocyte globulin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on antithymocyte globulin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call